User menu

What is the Need for Prostatic Biomarkers in Prostate Cancer Management?

Bibliographic reference Spahn, Martin ; Boxler, Silvan ; Joniau, Steven ; Moschini, Marco ; Tombal, Bertrand ; et. al. What is the Need for Prostatic Biomarkers in Prostate Cancer Management?. In: Current Urology Reports, Vol. 16, no.10, p. Article 70 (2015)
Permanent URL
  1. Ferlay J., Steliarova-Foucher E., Lortet-Tieulent J., Rosso S., Coebergh J.W.W., Comber H., Forman D., Bray F., Reprint of: Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012, 10.1016/j.ejca.2015.05.004
  2. Forbes S, Bindal N, Bamford S, et al. COSMIC: mining complete cancer genomes in the catalogue of somatic mutations in cancer. Nucleic Acids Res. 2011. doi: 10.1093/nar/gkq929 .
  3. Leinonen K. A., Saramaki O. R., Furusato B., Kimura T., Takahashi H., Egawa S., Suzuki H., Keiger K., Ho Hahm S., Isaacs W. B., Tolonen T. T., Stenman U.-H., Tammela T. L. J., Nykter M., Bova G. S., Visakorpi T., Loss of PTEN Is Associated with Aggressive Behavior in ERG-Positive Prostate Cancer, 10.1158/1055-9965.epi-13-0333-t
  4. Yoshimoto Maisa, Joshua Anthony M, Cunha Isabela W, Coudry Renata A, Fonseca Francisco P, Ludkovski Olga, Zielenska Maria, Soares Fernando A, Squire Jeremy A, Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome, 10.1038/modpathol.2008.96
  5. Krohn Antje, Diedler Tobias, Burkhardt Lia, Mayer Pascale-Sophie, De Silva Colin, Meyer-Kornblum Marie, Kötschau Darja, Tennstedt Pierre, Huang Joseph, Gerhäuser Clarissa, Mader Malte, Kurtz Stefan, Sirma Hüseyin, Saad Fred, Steuber Thomas, Graefen Markus, Plass Christoph, Sauter Guido, Simon Ronald, Minner Sarah, Schlomm Thorsten, Genomic Deletion of PTEN Is Associated with Tumor Progression and Early PSA Recurrence in ERG Fusion-Positive and Fusion-Negative Prostate Cancer, 10.1016/j.ajpath.2012.04.026
  6. McCall P, Witton C J, Grimsley S, Nielsen K V, Edwards J, Is PTEN loss associated with clinical outcome measures in human prostate cancer?, 10.1038/sj.bjc.6604680
  7. Burdelski Christoph, Bujupi Erzen, Tsourlakis Maria Christina, Hube-Magg Claudia, Kluth Martina, Melling Nathaniel, Lebok Patrick, Minner Sarah, Koop Christina, Graefen Markus, Heinzer Hans, Wittmer Corinna, Sauter Guido, Wilczak Waldemar, Simon Ronald, Schlomm Thorsten, Steurer Stefan, Krech Till, Loss of SOX9 Expression Is Associated with PSA Recurrence in ERG-Positive and PTEN Deleted Prostate Cancers, 10.1371/journal.pone.0128525
  8. Steurer Stefan, Mayer Pascale Sophia, Adam Meike, Krohn Antje, Koop Christina, Ospina-Klinck Daniel, Tehrani Ali Attarchi, Simon Ronald, Tennstedt Pierre, Graefen Markus, Wittmer Corinna, Brors Benedikt, Plass Christoph, Korbel Jan, Weischenfeldt Joachim, Sauter Guido, Huland Hartwig, Tsourlakis Maria Christina, Minner Sarah, Schlomm Thorsten, TMPRSS2-ERG Fusions Are Strongly Linked to Young Patient Age in Low-grade Prostate Cancer, 10.1016/j.eururo.2014.06.027
  9. Hoogland A Marije, Jenster Guido, van Weerden Wytske M, Trapman Jan, van der Kwast Theo, Roobol Monique J, Schröder Fritz H, Wildhagen Mark F, van Leenders Geert JLH, ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer, 10.1038/modpathol.2011.176
  10. Demichelis F, Fall K, Perner S, Andrén O, Schmidt F, Setlur S R, Hoshida Y, Mosquera J-M, Pawitan Y, Lee C, Adami H-O, Mucci L A, Kantoff P W, Andersson S-O, Chinnaiyan A M, Johansson J-E, Rubin M A, TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort, 10.1038/sj.onc.1210237
  11. Minner S., Enodien M., Sirma H., Luebke A. M., Krohn A., Mayer P. S., Simon R., Tennstedt P., Muller J., Scholz L., Brase J. C., Liu A. Y., Schluter H., Pantel K., Schumacher U., Bokemeyer C., Steuber T., Graefen M., Sauter G., Schlomm T., ERG Status Is Unrelated to PSA Recurrence in Radically Operated Prostate Cancer in the Absence of Antihormonal Therapy, 10.1158/1078-0432.ccr-11-1251
  12. Dal Pra A., Lalonde E., Sykes J., Warde F., Ishkanian A., Meng A., Maloff C., Srigley J., Joshua A. M., Petrovics G., van der Kwast T., Evans A., Milosevic M., Saad F., Collins C., Squire J., Lam W., Bismar T. A., Boutros P. C., Bristow R. G., TMPRSS2-ERG Status Is Not Prognostic Following Prostate Cancer Radiotherapy: Implications for Fusion Status and DSB Repair, 10.1158/1078-0432.ccr-13-1049
  13. FitzGerald Liesel M, Agalliu Ilir, Johnson Karynn, Miller Melinda A, Kwon Erika M, Hurtado-Coll Antonio, Fazli Ladan, Rajput Ashish B, Gleave Martin E, Cox Michael E, Ostrander Elaine A, Stanford Janet L, Huntsman David G, Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer, 10.1186/1471-2407-8-230
  14. Kalogirou Charis, Spahn Martin, Krebs Markus, Joniau Steven, Lerut Evelyne, Burger Maximilian, Scholz Claus-Jürgen, Kneitz Susanne, Riedmiller Hubertus, Kneitz Burkhard, MiR-205 Is Progressively Down-Regulated in Lymph Node Metastasis but Fails as a Prognostic Biomarker in High-Risk Prostate Cancer, 10.3390/ijms141121414
  15. Schubert M, Spahn M, Kneitz S, Scholz CJ, Joniau S, Stroebel P, et al. Distinct microRNA expression profile in prostate cancer patients with early clinical failure and the impact of let-7 as prognostic marker in high-risk prostate cancer. PLoS ONE. 2013;8, e65064.
  16. Spahn M, Kneitz S, Scholz C-JJ, Stenger N, Rüdiger T, Ströbel P, et al. Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence. Int J Cancer. 2010;127:394–403.
  17. Kneitz B, Krebs M, Kalogirou C, et al. Survival in patients with high-risk prostate cancer is predicted by miR-221, which regulates proliferation, apoptosis, and invasion of prostate cancer cells by inhibiting IRF2 and SOCS3. Cancer Res. 2014;74:2591–603. These analyzis are standing out for several reasons. First, the described single biomarker had a high prediction of cancer related death (AUC 90.3 %). Second, these results were confirmed by an external validation in an independent cohort. Third, the reported functional analysis demonstrated the biological function of this biomarker as a tumor suppressor regulating the JAK/STAT signaling pathway and sensitization to interferon-gamma treatment. Thus offering the chance for new treatment modalities in the future.
  18. Haffner Michael C., Mosbruger Timothy, Esopi David M., Fedor Helen, Heaphy Christopher M., Walker David A., Adejola Nkosi, Gürel Meltem, Hicks Jessica, Meeker Alan K., Halushka Marc K., Simons Jonathan W., Isaacs William B., De Marzo Angelo M., Nelson William G., Yegnasubramanian Srinivasan, Tracking the clonal origin of lethal prostate cancer, 10.1172/jci70354
  19. Kumar A., White T. A., MacKenzie A. P., Clegg N., Lee C., Dumpit R. F., Coleman I., Ng S. B., Salipante S. J., Rieder M. J., Nickerson D. A., Corey E., Lange P. H., Morrissey C., Vessella R. L., Nelson P. S., Shendure J., Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers, 10.1073/pnas.1108745108
  20. Alshalalfa M, Crisan A, Vergara IA, et al. Clinical and genomic analysis of metastatic prostate cancer progression with a background of postoperative biochemical recurrence. BJU Int. 2014. doi: 10.1111/bju.13013 .
  21. Erho Nicholas, Crisan Anamaria, Vergara Ismael A., Mitra Anirban P., Ghadessi Mercedeh, Buerki Christine, Bergstralh Eric J., Kollmeyer Thomas, Fink Stephanie, Haddad Zaid, Zimmermann Benedikt, Sierocinski Thomas, Ballman Karla V., Triche Timothy J., Black Peter C., Karnes R. Jeffrey, Klee George, Davicioni Elai, Jenkins Robert B., Discovery and Validation of a Prostate Cancer Genomic Classifier that Predicts Early Metastasis Following Radical Prostatectomy, 10.1371/journal.pone.0066855
  22. Karnes R. Jeffrey, Bergstralh Eric J., Davicioni Elai, Ghadessi Mercedeh, Buerki Christine, Mitra Anirban P., Crisan Anamaria, Erho Nicholas, Vergara Ismael A., Lam Lucia L., Carlson Rachel, Thompson Darby J.S., Haddad Zaid, Zimmermann Benedikt, Sierocinski Thomas, Triche Timothy J., Kollmeyer Thomas, Ballman Karla V., Black Peter C., Klee George G., Jenkins Robert B., Validation of a Genomic Classifier that Predicts Metastasis Following Radical Prostatectomy in an At Risk Patient Population, 10.1016/j.juro.2013.06.017
  23. Ross A E, Feng F Y, Ghadessi M, Erho N, Crisan A, Buerki C, Sundi D, Mitra A P, Vergara I A, Thompson D J S, Triche T J, Davicioni E, Bergstralh E J, Jenkins R B, Karnes R J, Schaeffer E M, A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy, 10.1038/pcan.2013.49
  24. Den Robert B., Yousefi Kasra, Trabulsi Edouard J., Abdollah Firas, Choeurng Voleak, Feng Felix Y., Dicker Adam P., Lallas Costas D., Gomella Leonard G., Davicioni Elai, Karnes R. Jeffrey, Genomic Classifier Identifies Men With Adverse Pathology After Radical Prostatectomy Who Benefit From Adjuvant Radiation Therapy, 10.1200/jco.2014.59.0026
  25. Klein Eric A., Yousefi Kasra, Haddad Zaid, Choeurng Voleak, Buerki Christine, Stephenson Andrew J., Li Jianbo, Kattan Michael W., Magi-Galluzzi Cristina, Davicioni Elai, A Genomic Classifier Improves Prediction of Metastatic Disease Within 5 Years After Surgery in Node-negative High-risk Prostate Cancer Patients Managed by Radical Prostatectomy Without Adjuvant Therapy, 10.1016/j.eururo.2014.10.036
  26. Den Robert B., Feng Felix Y., Showalter Timothy N., Mishra Mark V., Trabulsi Edouard J., Lallas Costas D., Gomella Leonard G., Kelly W. Kevin, Birbe Ruth C., McCue Peter A., Ghadessi Mercedeh, Yousefi Kasra, Davicioni Elai, Knudsen Karen E., Dicker Adam P., Genomic Prostate Cancer Classifier Predicts Biochemical Failure and Metastases in Patients After Postoperative Radiation Therapy, 10.1016/j.ijrobp.2014.04.052
  27. Cooperberg M, Davicioni E, Crisan, et al. Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort. Eur Urol. 2015;67(2):326–33. This report is of importance because it demonstrated the added value of this test to a standard clinical classification system.
  28. Cullen Jennifer, Rosner Inger L., Brand Timothy C., Zhang Nan, Tsiatis Athanasios C., Moncur Joel, Ali Amina, Chen Yongmei, Knezevic Dejan, Maddala Tara, Lawrence H. Jeffrey, Febbo Phillip G., Srivastava Shiv, Sesterhenn Isabell A., McLeod David G., A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer, 10.1016/j.eururo.2014.11.030
  29. Cuzick Jack, Dowsett Mitch, Pineda Silvia, Wale Christopher, Salter Janine, Quinn Emma, Zabaglo Lila, Mallon Elizabeth, Green Andrew R., Ellis Ian O., Howell Anthony, Buzdar Aman U., Forbes John F., Prognostic Value of a Combined Estrogen Receptor, Progesterone Receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and Comparison With the Genomic Health Recurrence Score in Early Breast Cancer, 10.1200/jco.2010.31.2835
  30. Cuzick Jack, Swanson Gregory P, Fisher Gabrielle, Brothman Arthur R, Berney Daniel M, Reid Julia E, Mesher David, Speights VO, Stankiewicz Elzbieta, Foster Christopher S, Møller Henrik, Scardino Peter, Warren Jorja D, Park Jimmy, Younus Adib, Flake Darl D, Wagner Susanne, Gutin Alexander, Lanchbury Jerry S, Stone Steven, Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study, 10.1016/s1470-2045(10)70295-3
  31. Cooperberg Matthew R., Simko Jeffry P., Cowan Janet E., Reid Julia E., Djalilvand Azita, Bhatnagar Satish, Gutin Alexander, Lanchbury Jerry S., Swanson Gregory P., Stone Steven, Carroll Peter R., Validation of a Cell-Cycle Progression Gene Panel to Improve Risk Stratification in a Contemporary Prostatectomy Cohort, 10.1200/jco.2012.46.4396
  32. Freedland Stephen J., Gerber Leah, Reid Julia, Welbourn William, Tikishvili Eliso, Park Jimmy, Younus Adib, Gutin Alexander, Sangale Zaina, Lanchbury Jerry S., Salama Joseph K., Stone Steven, Prognostic Utility of Cell Cycle Progression Score in Men With Prostate Cancer After Primary External Beam Radiation Therapy, 10.1016/j.ijrobp.2013.04.043
  33. Crawford E. David, Scholz Mark C., Kar Ashok J., Fegan Jeffrey E., Haregewoin Abebe, Kaldate Rajesh R., Brawer Michael K., Cell cycle progression score and treatment decisions in prostate cancer: results from an ongoing registry, 10.1185/03007995.2014.899208
  34. Grasso Catherine S., Wu Yi-Mi, Robinson Dan R., Cao Xuhong, Dhanasekaran Saravana M., Khan Amjad P., Quist Michael J., Jing Xiaojun, Lonigro Robert J., Brenner J. Chad, Asangani Irfan A., Ateeq Bushra, Chun Sang Y., Siddiqui Javed, Sam Lee, Anstett Matt, Mehra Rohit, Prensner John R., Palanisamy Nallasivam, Ryslik Gregory A., Vandin Fabio, Raphael Benjamin J., Kunju Lakshmi P., Rhodes Daniel R., Pienta Kenneth J., Chinnaiyan Arul M., Tomlins Scott A., The mutational landscape of lethal castration-resistant prostate cancer, 10.1038/nature11125
  35. Taylor Barry S., Schultz Nikolaus, Hieronymus Haley, Gopalan Anuradha, Xiao Yonghong, Carver Brett S., Arora Vivek K., Kaushik Poorvi, Cerami Ethan, Reva Boris, Antipin Yevgeniy, Mitsiades Nicholas, Landers Thomas, Dolgalev Igor, Major John E., Wilson Manda, Socci Nicholas D., Lash Alex E., Heguy Adriana, Eastham James A., Scher Howard I., Reuter Victor E., Scardino Peter T., Sander Chris, Sawyers Charles L., Gerald William L., Integrative Genomic Profiling of Human Prostate Cancer, 10.1016/j.ccr.2010.05.026
  36. Lapointe J., Li C., Giacomini C. P., Salari K., Huang S., Wang P., Ferrari M., Hernandez-Boussard T., Brooks J. D., Pollack J. R., Genomic Profiling Reveals Alternative Genetic Pathways of Prostate Tumorigenesis, 10.1158/0008-5472.can-07-0673
  37. Boutros Paul C, Fraser Michael, Harding Nicholas J, de Borja Richard, Trudel Dominique, Lalonde Emilie, Meng Alice, Hennings-Yeomans Pablo H, McPherson Andrew, Sabelnykova Veronica Y, Zia Amin, Fox Natalie S, Livingstone Julie, Shiah Yu-Jia, Wang Jianxin, Beck Timothy A, Have Cherry L, Chong Taryne, Sam Michelle, Johns Jeremy, Timms Lee, Buchner Nicholas, Wong Ada, Watson John D, Simmons Trent T, P'ng Christine, Zafarana Gaetano, Nguyen Francis, Luo Xuemei, Chu Kenneth C, Prokopec Stephenie D, Sykes Jenna, Dal Pra Alan, Berlin Alejandro, Brown Andrew, Chan-Seng-Yue Michelle A, Yousif Fouad, Denroche Robert E, Chong Lauren C, Chen Gregory M, Jung Esther, Fung Clement, Starmans Maud H W, Chen Hanbo, Govind Shaylan K, Hawley James, D'Costa Alister, Pintilie Melania, Waggott Daryl, Hach Faraz, Lambin Philippe, Muthuswamy Lakshmi B, Cooper Colin, Eeles Rosalind, Neal David, Tetu Bernard, Sahinalp Cenk, Stein Lincoln D, Fleshner Neil, Shah Sohrab P, Collins Colin C, Hudson Thomas J, McPherson John D, van der Kwast Theodorus, Bristow Robert G, Spatial genomic heterogeneity within localized, multifocal prostate cancer, 10.1038/ng.3315
  38. Robinson Dan, Van Allen Eliezer M., Wu Yi-Mi, Schultz Nikolaus, Lonigro Robert J., Mosquera Juan-Miguel, Montgomery Bruce, Taplin Mary-Ellen, Pritchard Colin C., Attard Gerhardt, Beltran Himisha, Abida Wassim, Bradley Robert K., Vinson Jake, Cao Xuhong, Vats Pankaj, Kunju Lakshmi P., Hussain Maha, Feng Felix Y., Tomlins Scott A., Cooney Kathleen A., Smith David C., Brennan Christine, Siddiqui Javed, Mehra Rohit, Chen Yu, Rathkopf Dana E., Morris Michael J., Solomon Stephen B., Durack Jeremy C., Reuter Victor E., Gopalan Anuradha, Gao Jianjiong, Loda Massimo, Lis Rosina T., Bowden Michaela, Balk Stephen P., Gaviola Glenn, Sougnez Carrie, Gupta Manaswi, Yu Evan Y., Mostaghel Elahe A., Cheng Heather H., Mulcahy Hyojeong, True Lawrence D., Plymate Stephen R., Dvinge Heidi, Ferraldeschi Roberta, Flohr Penny, Miranda Susana, Zafeiriou Zafeiris, Tunariu Nina, Mateo Joaquin, Perez-Lopez Raquel, Demichelis Francesca, Robinson Brian D., Schiffman Marc, Nanus David M., Tagawa Scott T., Sigaras Alexandros, Eng Kenneth W., Elemento Olivier, Sboner Andrea, Heath Elisabeth I., Scher Howard I., Pienta Kenneth J., Kantoff Philip, de Bono Johann S., Rubin Mark A., Nelson Peter S., Garraway Levi A., Sawyers Charles L., Chinnaiyan Arul M., Integrative Clinical Genomics of Advanced Prostate Cancer, 10.1016/j.cell.2015.05.001
  39. Fizazi Karim, Scher Howard I, Molina Arturo, Logothetis Christopher J, Chi Kim N, Jones Robert J, Staffurth John N, North Scott, Vogelzang Nicholas J, Saad Fred, Mainwaring Paul, Harland Stephen, Goodman Oscar B, Sternberg Cora N, Li Jin Hui, Kheoh Thian, Haqq Christopher M, de Bono Johann S, Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study, 10.1016/s1470-2045(12)70379-0
  40. Scher Howard I., Fizazi Karim, Saad Fred, Taplin Mary-Ellen, Sternberg Cora N., Miller Kurt, de Wit Ronald, Mulders Peter, Chi Kim N., Shore Neal D., Armstrong Andrew J., Flaig Thomas W., Fléchon Aude, Mainwaring Paul, Fleming Mark, Hainsworth John D., Hirmand Mohammad, Selby Bryan, Seely Lynn, de Bono Johann S., Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy, 10.1056/nejmoa1207506
  41. Enzalutamide in Metastatic Prostate Cancer before Chemotherapy, 10.1056/nejmc1410239
  42. Tannock Ian F., de Wit Ronald, Berry William R., Horti Jozsef, Pluzanska Anna, Chi Kim N., Oudard Stephane, Théodore Christine, James Nicholas D., Turesson Ingela, Rosenthal Mark A., Eisenberger Mario A., Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer, 10.1056/nejmoa040720
  43. de Bono Johann Sebastian, Oudard Stephane, Ozguroglu Mustafa, Hansen Steinbjørn, Machiels Jean-Pascal, Kocak Ivo, Gravis Gwenaëlle, Bodrogi Istvan, Mackenzie Mary J, Shen Liji, Roessner Martin, Gupta Sunil, Sartor A Oliver, Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial, 10.1016/s0140-6736(10)61389-x
  44. Tannock Ian F, Fizazi Karim, Ivanov Sergey, Karlsson Camilla Thellenberg, Fléchon Aude, Skoneczna Iwona, Orlandi Francisco, Gravis Gwenaelle, Matveev Vsevolod, Bavbek Sevil, Gil Thierry, Viana Luciano, Arén Osvaldo, Karyakin Oleg, Elliott Tony, Birtle Alison, Magherini Emmanuelle, Hatteville Laurence, Petrylak Daniel, Tombal Bertrand, Rosenthal Mark, Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial, 10.1016/s1470-2045(13)70184-0
  45. Quinn David I, Tangen Catherine M, Hussain Maha, Lara Primo N, Goldkorn Amir, Moinpour Carol M, Garzotto Mark G, Mack Philip C, Carducci Michael A, Monk J Paul, Twardowski Przemyslaw W, Van Veldhuizen Peter J, Agarwal Neeraj, Higano Celestia S, Vogelzang Nicholas J, Thompson Ian M, Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial, 10.1016/s1470-2045(13)70294-8
  46. Fizazi Karim, Higano Celestia S., Nelson Joel B., Gleave Martin, Miller Kurt, Morris Thomas, Nathan Faith E., McIntosh Stuart, Pemberton Kristine, Moul Judd W., Phase III, Randomized, Placebo-Controlled Study of Docetaxel in Combination With Zibotentan in Patients With Metastatic Castration-Resistant Prostate Cancer, 10.1200/jco.2012.46.4149
  47. Araujo John C, Trudel Géralyn C, Saad Fred, Armstrong Andrew J, Yu Evan Y, Bellmunt Joaquim, Wilding George, McCaffrey John, Serrano Sergio V, Matveev Vsevolod B, Efstathiou Eleni, Oudard Stephane, Morris Michael J, Sizer Bruce, Goebell Peter J, Heidenreich Axel, de Bono Johann S, Begbie Stephen, Hong Jun H, Richardet Eduardo, Gallardo Enrique, Paliwal Prashni, Durham Susan, Cheng Shinta, Logothetis Christopher J, Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial, 10.1016/s1470-2045(13)70479-0
  48. Petrylak Daniel P, Vogelzang Nicholas J, Budnik Nikolay, Wiechno Pawel Jan, Sternberg Cora N, Doner Kevin, Bellmunt Joaquim, Burke John M, de Olza Maria Ochoa, Choudhury Ananya, Gschwend Juergen E, Kopyltsov Evgeny, Flechon Aude, Van As Nicolas, Houede Nadine, Barton Debora, Fandi Abderrahim, Jungnelius Ulf, Li Shaoyi, de Wit Ronald, Fizazi Karim, Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial, 10.1016/s1470-2045(15)70025-2
  49. Michaelson M. Dror, Oudard Stephane, Ou Yen-Chuan, Sengeløv Lisa, Saad Fred, Houede Nadine, Ostler Peter, Stenzl Arnulf, Daugaard Gedske, Jones Robert, Laestadius Fredrik, Ullèn Anders, Bahl Amit, Castellano Daniel, Gschwend Juergen, Maurina Tristan, Chow Maneval Edna, Wang Shaw-Ling, Lechuga Maria Jose, Paolini Jolanda, Chen Isan, Randomized, Placebo-Controlled, Phase III Trial of Sunitinib Plus Prednisone Versus Prednisone Alone in Progressive, Metastatic, Castration-Resistant Prostate Cancer, 10.1200/jco.2012.48.5268
  50. Lacombe Denis, Tejpar Sabine, Salgado Roberto, Cardoso Fatima, Golfinopoulos Vassilis, Aust Daniela, Folprecht Gunnar, Roth Arnaud, Stupp Roger, European perspective for effective cancer drug development, 10.1038/nrclinonc.2014.98